1. Dexverapamil: A clinical approach to circumvention of multidrug resistance

   • William S. Dalton
   • Manfred Lehnert

   Preface Pages: R1 - R1

2. Dexverapamil to overcome epirubicin resistance in advanced breast cancer

   • B. Thürlimann
   • N. Kröger
   • M. Lehnert

   Original Paper Pages: R3 - R6

3. Phase I/II trial of dexverapamil, epirubicin and granulocyte/macrophage-colony-stimulating factor in patients with advanced pancreatic adenocarcinoma

   • W. Scheithauer
   • G. Kornek
   • C. Tetzner

   Original Article Pages: R7 - R10

4. Dexverapamil to modulate vinblastine resistance in metastatic renal cell carcinoma

   • G. H. Mickisch
   • M. A. Noordzij
   • F. H. Schröder

   Original Paper Pages: R11 - R16

5. Randomised trial of vindesine and etoposide ± dexverapamil in advanced non-small cell lung cancer: First results

   • U. Gatzemeier
   • A. Schneider
   • J. v. Pawel

   Original Paper Pages: R17 - R20

6. Dexverapamil as resistance modifier in acute myeloid leukaemia

   • R. Pirker
   • S. Zöchbauer
   • K. Lechner

   Original Paper Pages: R21 - R24

7. Modulation of multidrug resistance by dexverapamil in EPOCH-refractory lymphomas

   • Wyndham H. Wilson
   • Susan E. Bates
   • Bruce A. Chabner

   Original Paper Pages: R25 - R29